Molecular and Genetic studies in Gynaecological Malignancies

Molecular and genetic studies in gynecological malignancies have revolutionized diagnostics, prognostics, and targeted therapies. Advances in genomic sequencing have identified key mutations in ovarian (BRCA1/2, TP53), endometrial (PTEN, MSI), and cervical cancers (HPV integration, PIK3CA). These findings aid in precision medicine, guiding individualized treatments like PARP inhibitors for BRCA-mutated ovarian cancer. Epigenetic modifications, including DNA methylation and miRNA regulation, further influence tumor progression and therapeutic response. Emerging technologies like liquid biopsies and multi-omics approaches enhance early detection and monitoring. Understanding these molecular pathways is crucial for developing novel therapies and improving survival outcomes in gynecological malignancies.